title: GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption.
abstract: BACKGROUND
  Obinutuzumab (GA101) is a novel anti-CD20 monoclonal antibody that has been shown to be effective for the treatment of non-Hodgkin's lymphoma, and is currently being evaluated in phase 3 clinical trials. The side-effect profile of the drug is not yet well established.
  
  
  METHODS
  The authors report a case of a 62-year-old patient who developed widespread lichenoid eruption as a result of GA101 treatment for his follicular non-Hodgkin's lymphoma.
  
  
  CONCLUSIONS
  This is the first case report of cutaneous side effects of GA101.
authors.affiliation: Department of Dermatology, Burnley General Hospital, Burnley, UK.
authors.forename: Waseem
authors.initials: W
authors.lastname: Bakkour
authors.forename: Ian H
authors.initials: IH
authors.lastname: Coulson